Effects of Local Treatment in Combination with Systemic Therapy for Advanced Esophageal Cancer: A Systematic Review and Meta-analysis

Overview

Journal Adv Radiat Oncol

Specialty Oncology

Date 2024 Jun 3

PMID 38826154

Authors

Jianrui Ji

Yunsong Liu

Yongxing Bao

Yu Men

Jun Wang

Zhouguang Hui

Affiliations

Soon will be listed here.

Abstract

Purpose: Initial studies investigating the combination of local and systemic treatments in advanced esophageal cancer (EC) have conflicting conclusions regarding survival benefits. The objective of this systematic review and meta-analysis is to assess the efficacy of the addition of local therapy to systemic treatments in patients with advanced EC.

Methods And Materials: A systematic literature search was conducted in the PubMed, EMBASE, and CENTRAL databases. Key eligibility criteria included studies that enrolled patients with histologically confirmed EC or esophagogastric junction cancer with metastasis or recurrence and compared survival benefits between the combined local and systemic treatment group and the systemic treatment alone group. Survival outcomes, represented by hazard ratios (HRs) of progression-free survival (PFS) and overall survival (OS), were pooled using a random effects model. The MINORS score was adopted for quality assessment. Risk of bias was statistically examined by Begg's and Egger's tests.

Results: A total of 1 randomized controlled trial (RCT) and 10 qualified retrospective studies including 14,489 patients were identified. Addition of local therapy to systemic treatment significantly improved PFS (HR, 0.52; 95% CI, 0.37-0.73; < .001) and OS (HR, 0.69; 95% CI, 0.58-0.81; < .0001) compared with systemic treatment alone. The subgroup analysis revealed that combined local and systemic treatment conferred a significant survival advantage in both patients with oligometastasis (PFS: HR, 0.45; 95% CI, 0.31-0.64; < .0001; OS: HR, 0.62; 95% CI, 0.48-0.79; < .0001) and recurrence (OS: HR, 0.55; 95% CI, 0.37-0.81; = .002).

Conclusions: In conclusion, addition of local treatment to systemic therapy can improve survival in patients with advanced EC, particularly in those with oligometastasis or recurrent diseases.

Citing Articles

Radiotherapy combined with chemoimmunotherapy improves survival compared to chemoimmunotherapy alone as first-line treatment for oligometastatic esophageal squamous cell carcinoma.

Lv X, Wang S, Zhang W, Pang Q, Lin Q, Wu Y Strahlenther Onkol. 2025; .

PMID: 39805975 DOI: 10.1007/s00066-024-02347-y.

References

Shao Y, Zhang M, Ye L, Chen D, Wu Q, Zhang C . Survival differences between chemotherapy and chemoradiotherapy in metastatic esophageal cancer: a propensity score-matched study based on the SEER database. Ann Palliat Med. 2021; 10(4):3826-3835. DOI: 10.21037/apm-20-2126. View

Ajani J, DAmico T, Bentrem D, Cooke D, Corvera C, Das P . Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(4):393-422. DOI: 10.6004/jnccn.2023.0019. View

Qiu G, Zhang H, Wang F, Zheng Y, Wang Z, Wang Y . Metastasis Patterns and Prognosis of Elderly Patients With Esophageal Adenocarcinoma in Stage IVB: A Population-Based Study. Front Oncol. 2021; 11:625720. PMC: 8193932. DOI: 10.3389/fonc.2021.625720. View

Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J . Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003; 73(9):712-6. DOI: 10.1046/j.1445-2197.2003.02748.x. View

Kroese T, van Laarhoven H, Nilsson M, Lordick F, Guckenberger M, Ruurda J . Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis. Eur J Cancer. 2022; 166:254-269. DOI: 10.1016/j.ejca.2022.02.018. View

Liu Q, Chen J, Lin Y, Ye J, Shen W, Luo H . Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023; 9(1):45-55. DOI: 10.1016/S2468-1253(23)00316-3. View

Guo J, Zhang S, Li H, Hassan M, Lu T, Zhao J . Lung Metastases in Newly Diagnosed Esophageal Cancer: A Population-Based Study. Front Oncol. 2021; 11:603953. PMC: 7947855. DOI: 10.3389/fonc.2021.603953. View

Zhao W, Ke S, Cai X, Zuo Z, Shi W, Qiu H . Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: An open-label, single-arm, phase II trial. Radiother Oncol. 2023; 184:109679. DOI: 10.1016/j.radonc.2023.109679. View

Guttmann D, Mitra N, Bekelman J, Metz J, Plastaras J, Feng W . Improved Overall Survival with Aggressive Primary Tumor Radiotherapy for Patients with Metastatic Esophageal Cancer. J Thorac Oncol. 2017; 12(7):1131-1142. DOI: 10.1016/j.jtho.2017.03.026. View

10.

Kroese T, Buijs G, Burger M, Ruurda J, Mook S, Brosens L . Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer. Ann Surg Oncol. 2022; 29(8):4848-4857. PMC: 9246791. DOI: 10.1245/s10434-022-11541-0. View

11.

Qiu G, Zhang H, Wang F, Zheng Y, Wang Y . Patterns of metastasis and prognosis of elderly esophageal squamous cell carcinoma patients in stage IVB: a population-based study. Transl Cancer Res. 2022; 10(11):4591-4600. PMC: 8798664. DOI: 10.21037/tcr-21-1128. View

12.

Chen Y, Cheng X, Song H, Wu A, Ku G, Lee P . Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases. J Thorac Dis. 2019; 11(4):1536-1545. PMC: 6531702. DOI: 10.21037/jtd.2019.03.10. View

13.

Depypere L, Lerut T, Moons J, Coosemans W, Decker G, Van Veer H . Isolated local recurrence or solitary solid organ metastasis after esophagectomy for cancer is not the end of the road. Dis Esophagus. 2016; 30(1):1-8. DOI: 10.1111/dote.12508. View

14.

Tian G, Miu M, Huang X . Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev. 2014; 15(19):8475-8. DOI: 10.7314/apjcp.2014.15.19.8475. View

15.

Wu X, Li Y, Zhang K, Guo Z, Li Y, Zhao F . Immunotherapy with or without radiotherapy for metastatic or recurrent esophageal squamous cell carcinoma: A real-world study. Clin Transl Radiat Oncol. 2022; 38:130-137. PMC: 9678957. DOI: 10.1016/j.ctro.2022.10.011. View

16.

Morinaga T, Iwatsuki M, Yamashita K, Harada K, Kurashige J, Nagai Y . Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma. Surg Today. 2020; 51(5):798-806. DOI: 10.1007/s00595-020-02173-6. View

17.

Lyu J, Li T, Wang Q, Li F, Diao P, Liu L . Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study. Radiat Oncol. 2018; 13(1):233. PMC: 6257959. DOI: 10.1186/s13014-018-1183-y. View

18.

Ryckman J, Thomas T, Wang M, Wu X, Siva S, Spratt D . Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. Int J Radiat Oncol Biol Phys. 2022; 114(5):919-935. DOI: 10.1016/j.ijrobp.2022.06.095. View

19.

Li X, Zhang H, Jia X, Xu L, Liu H, Chen L . Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study. Transl Cancer Res. 2022; 8(4):1074-1085. PMC: 8797641. DOI: 10.21037/tcr.2019.06.15. View

20.

Shi Z, Zhu X, Ruan C, Wei G, Li J, Qiu H . Evaluation of Concurrent Chemoradiotherapy for Survival Outcomes in Patients With Synchronous Oligometastatic Esophageal Squamous Cell Carcinoma. JAMA Netw Open. 2022; 5(12):e2244619. PMC: 9716398. DOI: 10.1001/jamanetworkopen.2022.44619. View